A study on the safety and immune responses to the GVGH altSonflex1-2-3 vaccine against shigellosis in adults, children, and infants

Trial Identifier: 212149
Sponsor: GlaxoSmithKline
Start Date: October 2021
Primary Completion Date: June 2025
Study Completion Date: June 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Belgium Gent, Belgium, 9000
Kenya Kericho, Kenya, 20200